8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 31, 2026·SEC
Imunon, Inc.(IMNN)Earnings, Financials & Key Ratios
IMNN•NASDAQ
$1.79
Price updated Jun 27, 2026
AboutImunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.Show more
- Revenue$0
- EBITDA-$14M+24.2%
- Net Income-$14M+22.2%
- EPS (Diluted)-6.83+67.6%
- ROE-256.41%-21.4%
IMNN Price & Volume
Imunon, Inc. (IMNN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Imunon Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Imunon remains a pre-commercial biotechnology entity entirely dependent on external capital to fund its TheraPlas platform and GEN-1 clinical programs. The company faces significant binary risk as it attempts to navigate high-cost clinical trials without any revenue generation, leading to a cumulative retained earnings deficit of $425.5 million. Investors should monitor the company's narrow liquidity buffer, as the current cash position of $4.8 million appears insufficient to sustain operations without further dilutive financing."
Verdict Logic
the company's cash reserves have dwindled to $4.8 million as of 2026Q1, creating a precarious liquidity position that necessitates immediate and potentially dilutive capital raises to avoid a cessation of clinical activities.
IMNN Growth Metrics
Imunon, Inc. (IMNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM68.07%
Return on Capital
10 Years-90.22%
5 Years-121.63%
3 Years-172.02%
Last Year-232.64%
IMNN Recent Earnings
Imunon, Inc. (IMNN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.84+30.9%
$1.22
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$1.29+9.8%
$1.43
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.16+32.9%
$1.73
Rev
—
—
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.87+39.5%
$3.09
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.84vs $1.22+30.9% | — |
| Q2 2026 | Mar 31, 2026 | $1.29vs $1.43+9.8% | — |
| Q4 2025 | Nov 13, 2025 | $1.16vs $1.73+32.9% | — |
| Q3 2025 | Aug 5, 2025 | $1.87vs $3.09+39.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Imunon, Inc. (IMNN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.79 | $4.51M | -0.26 | — | — | -256.41% | 0.27% | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — |
Compare IMNN vs Peers
Imunon, Inc. (IMNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMNN SEC Filings & Documents
Imunon, Inc. (IMNN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IMNN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMNN Frequently Asked Questions
Imunon, Inc. (IMNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IMNN profitable?
Imunon, Inc. (IMNN) reported a net loss of $14.6M for fiscal year 2025.
Dividend & Returns
Does IMNN pay dividends?
Yes, Imunon, Inc. (IMNN) pays a dividend with a yield of 0.27%. This makes it attractive for income-focused investors.
What is IMNN's return on equity?
Imunon, Inc. (IMNN) has a return on equity (ROE) of -256.4%. Negative ROE indicates the company is unprofitable.
What is Imunon, Inc.'s free cash flow?
Imunon, Inc. (IMNN) had negative free cash flow of $15.1M in fiscal year 2025, likely due to heavy capital investments.